SBIR-STTR Award

Brain Cancer Xenotransplant Model For Drug Screening
Award last edited on: 7/20/10

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$191,984
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Chungi Li

Company Information

Phylonix Pharmaceuticals Inc

100 Inman Street Suite 300
Cambridge, MA 02139
   (617) 441-6700
   info@phylonix.com
   www.phylonix.com
Location: Single
Congr. District: 07
County: Middlesex

Phase I

Contract Number: 1R43CA150293-01
Start Date: 5/7/10    Completed: 11/30/10
Phase I year
2010
Phase I Amount
$191,984
In this research, we will develop zebrafish as a new xenotransplant animal model to assess brain cancer progression and identify potential drug candidates. Brain cancer accounts for approximately 10 - 30% of adult cancers and many forms of cancer can metastasize to the brain. Although immunodeficient mice and rats have played an important role as hosts for brain cancer xenografts, a simple and cost-effective orthotopic brain cancer model is required for more efficient in vivo cancer drug screening.

Public Health Relevance:
In this research, we propose to develop zebrafish as a new xenotransplant animal model to assess brain cancer progression, identify potential drug candidates, and rank efficacy.

Thesaurus Terms:
21+ Years Old; Accounting; Adult; Animal Model; Animal Models And Related Studies; Animals; Anti-Cancer Agents; Anti-Tumor Agents; Anti-Tumor Drugs; Antineoplastic Agents; Antineoplastic Drugs; Antineoplastics; Antiproliferative Agents; Antiproliferative Drugs; Astrocytic Neoplasm; Astrocytic Tumor; Astrocytoma; Astrocytoma, Grade Iv; Astroglioma; Brachydanio Rerio; Brain; Brain Ventricle; Cm-Dii; Cancer Drug; Cancer Model; Cancer Cell Line; Cancer Of Brain; Cancermodel; Cancers; Cell Growth In Number; Cell Line; Cell Lines, Strains; Cell Multiplication; Cell Proliferation; Cellline; Cells; Cellular Proliferation; Cerebral Ventricles; Chemotherapeutic Agents, Neoplastic Disease; Coloring Agents; Common Rat Strains; Danio Rerio; Data; Development; Disease; Disorder; Drug Combinations; Drug Evaluation, Preclinical; Drug Screening; Drugs; Dyes; Elisa; Encephalon; Encephalons; Enzyme-Linked Immunosorbent Assay; Evaluation; Evaluation Studies, Drug, Pre-Clinical; Evaluation Studies, Drug, Preclinical; Fda Approved; Glioblastoma; Glioma, Astrocytic; Government; Grade Iv Astrocytic Neoplasm; Grade Iv Astrocytic Tumor; Heterograft; Hind Brain; Human; Human Migration / Distribution; Human, Adult; Human, General; Immunodeficient Mouse; Injection Of Therapeutic Agent; Injections; Label; Libraries; Life; Malignant; Malignant - Descriptor; Malignant Cell; Malignant Neoplasms; Malignant Tumor; Malignant Tumor Of The Brain; Malignant Neoplasm Of Brain; Mammalia; Mammals; Mammals, General; Mammals, Mice; Mammals, Rats; Man (Taxonomy); Man, Modern; Medication; Metastasis; Metastasize; Metastatic Neoplasm; Metastatic Tumor; Mice; Modeling; Murine; Mus; Neoplasm Metastasis; Nervous System, Brain; Persons; Pharmaceutic Preparations; Pharmaceutical Agent; Pharmaceutical Preparations; Pharmaceuticals; Pharmacologic Substance; Pharmacological Substance; Phase; Play; Preclinical Drug Evaluation; Proliferating; Publishing; Rat; Rattus; Research; Rhombencephalon; Role; Screening Procedure; Secondary Neoplasm; Secondary Tumor; Site; System; System, Loinc Axis 4; Transplantation, Heterologous; Tumor Cell Migration; Tumor-Specific Treatment Agents; Visual; Xenograft; Xenograft Procedure; Xenotransplantation; Zebra Danio; Zebra Fish; Zebrafish; Adult Human (21+); Angiogenesis; Anticancer Agent; Anticancer Drug; Anticancer Research; Base; Brain Cell; Cancer Cell; Cancer Metastasis; Cancer Progression; Cancer Research; Cost; Cultured Cell Line; Disease/Disorder; Drug Candidate; Drug/Agent; Glioblastoma Multiforme; Hindbrain; Human Migration; In Vivo; Malignancy; Medulloblastoma; Model Organism; Neoplasm Progression; Neoplasm/Cancer; Neoplastic Progression; Novel; Public Health Relevance; Screening; Screenings; Social Role; Spongioblastoma Multiforme; Tumor Progression

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----